[The results of the two-year experience of using keppra in therapy of adult patients with epilepsy].
Keppra (levetiracetam) was used as a part of the complex therapy in 87 patients with partial epilepsy and in 17 patients with adult idiopathic generalized epilepsy. Most of the cases were pharmacoresistant. Remission was observed in 25.3% of patients for the period over 12 months. Therapeutic efficacy by a decrease of seizures frequency by 75% and more has been reached in 12.6% of cases; by 50% and more--in 43.7%. The absence of drug effect and insufficient efficacy were detected only in 18.4% of cases. The therapeutic effect was stable and did not decrease after 12 and 24 months. The drug was well tolerated and was withdrawn in 5 cases (4.8%) because of side effects. The results obtained hold promise for using keppra in epileptology, in particular in treatment of pharmacoresistant epilepsy.